Numerous randomized trials have demonstrated that treatment with a statin reduces the risk of major cardiovascular events (MCE). We sought to quantitatively estimate the potential pleiotropic effect of statins by estimating the magnitude of this clinical benefit not related to the low-density lipoprotein cholesterol (LDL-C) lowering effects of statins.
Results:
In a meta-regression analysis of 26 statin trials involving 169,138 participants (Table) , treatment with a statin resulted in an 18% reduction in the risk of MCE per mmol/L reduction in LDL-C (RR: 0.82, 95%CI: 0.73-0.91), with no evidence of a significant additional pleiotropic effect (RR: 0.98, 95%CI: 0.89-1.09). In analyses that controlled for changes in HDL-C and TG, the effect of statin therapy per mmol/L reduction in LDL-C remained unchanged (RR: 0.83, 95%CI: 0.70-0.98), with no evidence for an additional pleiotropic effect (RR: 1.00, 95%CI: 0.88-1.13).
Conclusion:
The clinical benefit of statin therapy appears to be mediated almost entirely by reductions in LDL-C with no evidence of a significant additional potential pleiotropic effect. 
